Becton, Dickinson and Company $BDX Stock: State of Alaska Department of Revenue Boosts Position

State of Alaska Department of Revenue boosted its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 10.8% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 29,913 shares of the medical instruments supplier’s stock after buying an additional 2,915 shares during the period. State of Alaska Department of Revenue’s holdings in Becton, Dickinson and Company were worth $5,354,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the company. Auto Owners Insurance Co increased its stake in Becton, Dickinson and Company by 22,225.2% in the 4th quarter. Auto Owners Insurance Co now owns 40,711,035 shares of the medical instruments supplier’s stock worth $790,079,000 after acquiring an additional 40,528,680 shares during the last quarter. BlackRock Inc. purchased a new stake in shares of Becton, Dickinson and Company during the 2nd quarter worth approximately $3,721,533,000. Bank of America Corp DE bought a new position in shares of Becton, Dickinson and Company during the 2nd quarter valued at approximately $474,993,000. First Eagle Investment Management LLC boosted its position in shares of Becton, Dickinson and Company by 15.8% during the 2nd quarter. First Eagle Investment Management LLC now owns 13,815,335 shares of the medical instruments supplier’s stock valued at $2,090,675,000 after acquiring an additional 1,887,224 shares during the last quarter. Finally, Bank of New York Mellon Corp purchased a new position in shares of Becton, Dickinson and Company in the second quarter valued at $247,372,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Insider Buying and Selling at Becton, Dickinson and Company

In related news, CEO Thomas E. Polen, Jr. sold 4,152 shares of Becton, Dickinson and Company stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $185.00, for a total transaction of $768,120.00. Following the completion of the transaction, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at approximately $20,380,155. The trade was a 3.63% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the company’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total transaction of $440,887.92. Following the transaction, the executive vice president owned 14,856 shares in the company, valued at $2,686,559.04. The trade was a 14.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 6,906 shares of company stock worth $1,265,855 over the last quarter. Insiders own 0.40% of the company’s stock.

Analyst Ratings Changes

BDX has been the topic of several research reports. TD Cowen boosted their price target on shares of Becton, Dickinson and Company from $163.00 to $182.00 and gave the stock a “hold” rating in a research report on Wednesday, August 5th. Weiss Ratings raised shares of Becton, Dickinson and Company from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, September 28th. Stifel Nicolaus set a $195.00 price objective on shares of Becton, Dickinson and Company in a research report on Friday, August 7th. Bank of America lifted their price objective on shares of Becton, Dickinson and Company from $185.00 to $200.00 and gave the stock a “neutral” rating in a research note on Monday, August 31st. Finally, Barclays initiated coverage on shares of Becton, Dickinson and Company in a report on Wednesday, October 7th. They issued an “underweight” rating and a $165.00 target price on the stock. Seven research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $185.07.

Becton, Dickinson and Company Trading Down 1.3%

Shares of Becton, Dickinson and Company stock traded down $2.42 on Friday, reaching $191.34. The company had a trading volume of 1,412,670 shares, compared to its average volume of 1,816,545. The firm has a market cap of $52.72 billion, a price-to-earnings ratio of 57.63, a P/E/G ratio of 13.06 and a beta of 0.21. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51. The firm’s 50-day moving average price is $184.03 and its two-hundred day moving average price is $163.70. Becton, Dickinson and Company has a 1 year low of $127.59 and a 1 year high of $195.99.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, beating the consensus estimate of $3.14 by $0.09. The company had revenue of $4.98 billion for the quarter, compared to analyst estimates of $4.89 billion. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%. Becton, Dickinson and Company’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.68 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, research analysts predict that Becton, Dickinson and Company will post 12.67 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 9th were given a dividend of $1.05 per share. The ex-dividend date was Wednesday, September 9th. This represents a $4.20 dividend on an annualized basis and a yield of 2.2%. Becton, Dickinson and Company’s payout ratio is 126.51%.

About Becton, Dickinson and Company

Becton, Dickinson and Company, doing business as BD, is a global medical technology company that develops, manufactures and sells devices, diagnostic products and solutions for healthcare providers, researchers and patients. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, the company serves customers in hospitals, laboratories, physician offices, pharmacies and other healthcare settings worldwide.

BD’s Medical segment offers products used for medication delivery and management, including needles, syringes, infusion systems, medication preparation and dispensing technologies, and systems designed to help improve medication safety.